Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Authors
Keywords
-
Journal
European Respiratory Review
Volume 30, Issue 161, Pages 200294
Publisher
European Respiratory Society (ERS)
Online
2021-07-21
DOI
10.1183/16000617.0294-2020
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
- (2021) R. Soo et al. ANNALS OF ONCOLOGY
- ES28.05 Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors
- (2021) M. Molina-Arcas Journal of Thoracic Oncology
- MA11.07 Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors
- (2021) B.C. Cho et al. Journal of Thoracic Oncology
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- (2020) Misako Nagasaka et al. CANCER TREATMENT REVIEWS
- Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
- (2020) Adam J Schoenfeld et al. CLINICAL CANCER RESEARCH
- Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC
- (2020) Gonzalo Recondo et al. CLINICAL CANCER RESEARCH
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
- (2020) Benjamin J. Solomon et al. Journal of Thoracic Oncology
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
- (2020) Lecia V Sequist et al. LANCET ONCOLOGY
- Resistance looms for KRASG12C inhibitors
- (2020) Aaron N. Hata et al. NATURE MEDICINE
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- (2020) Alex Friedlaender et al. CANCER TREATMENT REVIEWS
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).
- (2020) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
- (2020) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
- (2020) Egbert F. Smit et al. JOURNAL OF CLINICAL ONCOLOGY
- NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
- (2020) Makoto Maemondo et al. JOURNAL OF CLINICAL ONCOLOGY
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
- (2020) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
- (2020) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- The force of HER2 – A druggable target in NSCLC?
- (2020) M. Jebbink et al. CANCER TREATMENT REVIEWS
- The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma
- (2020) Raul Caso et al. Journal of Thoracic Oncology
- Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
- (2020) J.J. Lin et al. ANNALS OF ONCOLOGY
- 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
- (2020) B.C. Cho et al. ANNALS OF ONCOLOGY
- LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
- (2020) H.A. Yu et al. ANNALS OF ONCOLOGY
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
- (2020) P.A. Jänne et al. EUROPEAN JOURNAL OF CANCER
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer
- (2019) Wenxia Su et al. MEDICINE
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
- (2019) A T Shaw et al. ANNALS OF ONCOLOGY
- Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
- (2019) Natasha B. Leighl et al. CLINICAL CANCER RESEARCH
- Effective cancer genotyping -- many means to one end
- (2019) Catherine B. Meador et al. CLINICAL CANCER RESEARCH
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Tissue-Specific Oncogenic Activity of KRASA146T
- (2019) Emily J. Poulin et al. Cancer Discovery
- Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
- (2019) Caicun Zhou et al. Lancet Respiratory Medicine
- Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
- (2019) Jeeyun Lee et al. Frontiers in Oncology
- Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
- (2019) Michael Offin et al. Journal of Thoracic Oncology
- Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2019) Emma Pailler et al. CLINICAL CANCER RESEARCH
- Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
- (2019) Jhanelle E. Gray et al. CLINICAL CANCER RESEARCH
- Capmatinib for the treatment of non-small cell lung cancer
- (2019) Johan Filip Vansteenkiste et al. Expert Review of Anticancer Therapy
- Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
- (2019) Vanita Noronha et al. JOURNAL OF CLINICAL ONCOLOGY
- TRK inhibitors in TRK fusion-positive cancers
- (2019) A Drilon ANNALS OF ONCOLOGY
- LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
- (2019) R Camidge et al. ANNALS OF ONCOLOGY
- LBA19Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
- (2019) T S K Mok et al. ANNALS OF ONCOLOGY
- Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer
- (2019) Vassiliki A. Papadimitrakopoulou et al. CANCER
- Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial
- (2019) Jaafar Bennouna et al. Clinical Lung Cancer
- MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer
- (2019) S. Ortiz-Cuaran et al. Journal of Thoracic Oncology
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
- (2019) A. Drilon et al. Journal of Thoracic Oncology
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
- (2019) Alice T Shaw et al. LANCET ONCOLOGY
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- (2019) Alexander Drilon et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
- (2018) Alessandro Leonetti et al. CANCER TREATMENT REVIEWS
- TargetingHER2Aberrations in Non–Small Cell Lung Cancer with Osimertinib
- (2018) Shengwu Liu et al. CLINICAL CANCER RESEARCH
- High-throughput functional evaluation of variants of unknown significance in ERBB2
- (2018) Masaaki Nagano et al. CLINICAL CANCER RESEARCH
- An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach
- (2018) Barbara Melosky et al. Clinical Lung Cancer
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
- (2018) Benjamin J. Solomon et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
- (2018) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
- (2018) Roberto Ferrara et al. Journal of Thoracic Oncology
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection and localization of surgically resectable cancers with a multi-analyte blood test
- (2018) Joshua D. Cohen et al. SCIENCE
- Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
- (2018) Franz L. Ricklefs et al. Science Advances
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
- (2018) Adrianus J. de Langen et al. BRITISH JOURNAL OF CANCER
- KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small-cell Lung Cancer
- (2018) Stéphane Renaud et al. Clinical Lung Cancer
- Lorlatinib in patients (Pts) with previously treated ALK+ advanced non-small cell lung cancer (NSCLC): Updated efficacy and safety.
- (2018) Benjamin Besse et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular characterization of cancers with NTRK gene fusions
- (2018) Zoran Gatalica et al. MODERN PATHOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors
- (2018) Kartik Sehgal et al. Translational Cancer Research
- LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
- (2018) S S Ramalingam et al. ANNALS OF ONCOLOGY
- Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA
- (2018) Jong Sik Lee et al. BMC CANCER
- EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
- (2018) Nicolas Marcoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- Current and future perspectives of liquid biopsies in genomics-driven oncology
- (2018) Ellen Heitzer et al. NATURE REVIEWS GENETICS
- Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
- (2017) Xian Chan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2017) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- (2017) Oliver Gautschi et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
- (2017) Sun Min Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
- (2017) Alexander Drilon et al. Journal of Thoracic Oncology
- Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review
- (2017) Adrian G. Sacher et al. Journal of Thoracic Oncology
- Recent Advances in Targeting ROS1 in Lung Cancer
- (2017) Jessica J. Lin et al. Journal of Thoracic Oncology
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Uncommon EGFR mutations in advanced non-small cell lung cancer
- (2017) Grainne M. O’Kane et al. LUNG CANCER
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations
- (2017) Frédéric Dugay et al. Oncotarget
- The frequency and clinical impact of HER2 alterations in lung adenocarcinoma
- (2017) Eun Kyung Kim et al. PLoS One
- Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboringRETrearrangement: a phase II clinical trial
- (2016) S.-H. Lee et al. ANNALS OF ONCOLOGY
- Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer
- (2016) Azusa Tanimoto et al. CLINICAL CANCER RESEARCH
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- A Case of ALK- Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
- (2016) Yoon Jin Cha et al. Journal of Thoracic Oncology
- Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients
- (2016) Sebastian Michels et al. Journal of Thoracic Oncology
- HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
- (2016) Bob T. Li et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma
- (2016) Charline Caumont et al. LUNG CANCER
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
- (2016) Jacob J. Chabon et al. Nature Communications
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
- (2016) Difan Zheng et al. Oncotarget
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer
- (2015) A. Song et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
- (2015) T. Mok et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
- (2015) Oliver Gautschi et al. Journal of Thoracic Oncology
- Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer
- (2015) Jie Ma et al. LABORATORY INVESTIGATION
- Frequent expression of PD-L1 on circulating breast cancer cells
- (2015) Martine Mazel et al. Molecular Oncology
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
- (2015) Akriti Kharbanda et al. Oncotarget
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
- (2014) Tomasz Powrózek et al. MEDICAL ONCOLOGY
- Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
- (2014) Seung Eun Lee et al. MODERN PATHOLOGY
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- HER2 and lung cancer
- (2013) Lorenza Landi et al. Expert Review of Anticancer Therapy
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer
- (2013) Riccardo Cazzoli et al. Journal of Thoracic Oncology
- Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny
- (2012) Kenichi Suda et al. CANCER AND METASTASIS REVIEWS
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFRmutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
- (2012) Gillian Ellison et al. JOURNAL OF CLINICAL PATHOLOGY
- Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
- (2012) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
- (2012) P. K. Paik et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer
- (2011) M. C. Garassino et al. ANNALS OF ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
- (2011) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
- (2010) Lingxiang Liu et al. Journal of Thoracic Oncology
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
- Activation of tyrosine kinases by mutation of the gatekeeper threonine
- (2008) Mohammad Azam et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started